NATIONAL INSTITUTES OF HEALTH
- Country
- πΊπΈUnited States
- Ownership
- Subsidiary, Private
- Established
- 1948-01-01
- Employees
- 1K
- Market Cap
- -
- Website
- http://www.nidcr.nih.gov
Ifosfamide With or Without O(6)-Benzylguanine in Treating Patients With Unresectable, Metastatic Solid Tumors
- Conditions
- Unspecified Adult Solid Tumor, Protocol Specific
- Interventions
- First Posted Date
- 2004-07-12
- Last Posted Date
- 2013-01-24
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 32
- Registration Number
- NCT00086970
- Locations
- πΊπΈ
University of Chicago Comprehensive Cancer Center, Chicago, Illinois, United States
Rebeccamycin Analog in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia, Myelodysplastic Syndrome, Acute Lymphoblastic Leukemia, or Chronic Myelogenous Leukemia
- Conditions
- Adult Acute Myeloid Leukemia With 11q23 (MLL) AbnormalitiesAdult Acute Myeloid Leukemia With Inv(16)(p13;q22)Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)Blastic Phase Chronic Myelogenous LeukemiaChronic Myelomonocytic Leukemiade Novo Myelodysplastic SyndromesPreviously Treated Myelodysplastic SyndromesRecurrent Adult Acute Lymphoblastic Leukemia
- Interventions
- Other: laboratory biomarker analysis
- First Posted Date
- 2004-07-12
- Last Posted Date
- 2013-01-23
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 40
- Registration Number
- NCT00087204
- Locations
- πΊπΈ
M D Anderson Cancer Center, Houston, Texas, United States
Rebeccamycin Analog and Oxaliplatin in Treating Patients With Refractory Solid Tumors
- Conditions
- Unspecified Adult Solid Tumor, Protocol Specific
- Interventions
- First Posted Date
- 2004-07-12
- Last Posted Date
- 2013-01-10
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 15
- Registration Number
- NCT00086983
- Locations
- πΊπΈ
Case Western Reserve University, Cleveland, Ohio, United States
Tanespimycin in Treating Patients With Stage III-IV Melanoma
- Conditions
- Recurrent MelanomaStage III MelanomaStage IV Melanoma
- Interventions
- Other: laboratory biomarker analysis
- First Posted Date
- 2004-07-12
- Last Posted Date
- 2013-04-10
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 50
- Registration Number
- NCT00087386
- Locations
- πΊπΈ
Memorial Sloan-Kettering Cancer Center, New York, New York, United States
S0341: Erlotinib in Treating Patients With Advanced Primary Non-Small Cell Lung Cancer
- Conditions
- Adenocarcinoma of the LungLarge Cell Lung CancerRecurrent Non-small Cell Lung CancerSquamous Cell Lung CancerStage IIIB Non-small Cell Lung CancerStage IV Non-small Cell Lung Cancer
- Interventions
- Other: laboratory biomarker analysis
- First Posted Date
- 2004-07-12
- Last Posted Date
- 2013-02-28
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 65
- Registration Number
- NCT00087412
- Locations
- πΊπΈ
Southwest Oncology Group, San Antonio, Texas, United States
Predictors of Relapse of Ovarian, Peritoneal, and Fallopian Tube Cancers
- Conditions
- Fallopian Tube CancerEpithelial Ovarian CancerPeritoneal Neoplasms
- First Posted Date
- 2004-07-05
- Last Posted Date
- 2025-06-17
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 119
- Registration Number
- NCT00086567
- Locations
- πΊπΈ
Pacific Ovarian Cancer Research Consortium at FHCRC, Seattle, Washington, United States
πΊπΈCedars Sinai Medical Center, Los Angeles, California, United States
πΊπΈFox Chase Cancer Center, Philadelphia, Pennsylvania, United States
Radiation Therapy and Chemotherapy in Treating Children With CNS Relapse From Acute Lymphoblastic Leukemia
- Conditions
- Leukemia
- Interventions
- Biological: filgrastimRadiation: low-LET electron therapyRadiation: low-LET photon therapy
- First Posted Date
- 2004-07-01
- Last Posted Date
- 2013-02-01
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 156
- Registration Number
- NCT00002704
- Locations
- πΊπΈ
West Virginia University Hospitals, Morgantown, West Virginia, United States
πΊπΈEmory University Hospital - Atlanta, Atlanta, Georgia, United States
πΊπΈMarlene & Stewart Greenebaum Cancer Center, University of Maryland, Baltimore, Maryland, United States
Topotecan in Treating Children With Refractory Leukemia
- First Posted Date
- 2004-07-01
- Last Posted Date
- 2013-02-01
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 3
- Registration Number
- NCT00002705
- Locations
- πΊπΈ
Emory University Hospital - Atlanta, Atlanta, Georgia, United States
π¨πClinique de Pediatrie, Geneva, Switzerland
πΊπΈRoswell Park Cancer Institute, Buffalo, New York, United States
Monoclonal Antibody Plus Chemotherapy in Treating Patients With Advanced Colorectal Cancer That Overexpresses HER2
- Conditions
- Colorectal Cancer
- Interventions
- Biological: trastuzumab
- First Posted Date
- 2004-06-25
- Last Posted Date
- 2013-02-08
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 32
- Registration Number
- NCT00003995
- Locations
- πΊπΈ
Sarah Cannon-Minnie Pearl Cancer Center, Nashville, Tennessee, United States
πΊπΈAlbert Einstein Comprehensive Cancer Center, Bronx, New York, United States
πΊπΈUniversity of Pittsburgh Cancer Institute, Pittsburgh, Pennsylvania, United States
Bryostatin-1 in Treating Patients With Recurrent Non-Hodgkin's Lymphoma
- First Posted Date
- 2004-06-23
- Last Posted Date
- 2013-02-05
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 35
- Registration Number
- NCT00002725
- Locations
- πΊπΈ
University of Texas - MD Anderson Cancer Center, Houston, Texas, United States